Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
Investing.com - 4basebio PLC (AIM:4BB), a life sciences service company specializing in synthetic DNA and delivery systems, on Tuesday reported a significant revenue increase for 2024, doubling its DNA sales compared to the previous year.
The company’s total revenue reached £933,000, marking substantial growth in its core business.
4basebio made notable strides in product supply for clinical trials, providing opDNA™ to HelixNano Technologies Inc. for an mRNA vaccine trial and supplying high-quality and GMP-grade synthetic DNA to a tier-one pharmaceutical company’s vaccine program.
These partnerships underscore the company’s growing presence in the cell and gene therapy market.
A key milestone for 4basebio was obtaining GMP manufacturing license approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), enhancing its capabilities to serve pharmaceutical clients.
The company also expanded its intellectual property portfolio to 29 patent families, reinforcing its position in synthetic DNA technology.
Dr. Heikki Lanckriet, CEO and CSO of 4basebio, commented, "2024 has been a transformational year of growth for 4basebio, closing the strategic investment by Elevage and M&G, securing MHRA certification and continuing to expand our commercial capabilities and client base."
The company successfully raised £40 million in primary equity investment in November 2024, providing capital for future growth initiatives. Additionally, 4basebio formed a Strategic Advisory Board to guide the company’s strategic direction.
While specific earnings per share figures were not provided, the substantial revenue growth and strategic developments suggest a positive trajectory for the company in the rapidly evolving cell and gene therapy sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.